Human growth hormone abuse in male weightlifters

American Journal on Addictions

Volumn 20, Issue 1, 2011, Pages 9-13

  Brennan, Brian P ^a,b   Kanayama, Gen ^a,b   Hudson, James I ^a,b   Pope Jr , Harrison G ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANABOLIC AGENT; ANDROGEN; COCAINE; HUMAN GROWTH HORMONE; OPIATE; SOMATOMEDIN C;

ADULT; ARTICLE; ATHLETE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PERFORMANCE; SUBSTANCE ABUSE; WEIGHT LIFTING;

ADOLESCENT; ADULT; ANABOLIC AGENTS; ANDROGENS; ATHLETES; DOPING IN SPORTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; SELF MEDICATION; SUBSTANCE-RELATED DISORDERS;

EID: 78650674515     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2010.00093.x     Document Type: Article

References (40)

1. Associated Press. Baseball's week of drug news. February 14, 2009.
2. Dahlberg T,. Marion Jones can't stop running with a lie. Associated Press. October 29, 2008.
3. Elitefitness.com Jintropin HGH: Real or fake? Available online at:. Accessed October 18, 2010.
4. Llewellyn W., Anabolics, 9th edn. Jupiter, Florida: Molecular Nutrition; 2009.
5. EC21 global B2B marketplace. Available at:. Accessed October 18, 2010.
6. Graham MR, Evans P, Davies B, et al,. AAS, growth hormone, and insulin abuse: Psychological and neuroendocrine effects. Ther Clinical Risk Manag. 2008; 4: 587-597.
7. Rickert VI, Pawlak-Morello C, Sheppard V, et al,. Human growth hormone: A new substance of abuse among adolescents? Clin Ped. 1992; 31: 723-726.
8. Wanjek B, Rosendahl J, Strauss B, et al,. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): Prevalence, knowledge and attitudes. Int J Sports Med. 2007; 28: 346-353.
9. Evans NA,. Gym and tonic: A profile of 100 male steroid users. Br J Sports Med. 1997; 31: 54-58.
10. Baker JS, Graham MR, Davies B,. Steroid and prescription medicine abuse in the health and fitness community: A regional study. Euro J Intern Med. 2006; 17: 479-484.
11. Pates R, Barry C,. Steroid use in Cardiff: A problem for whom? J Perform-Enhancing Drugs. 1996; 1: 92-97.
12. Gruber AJ, Pope HG, Jr,. Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom. 2000; 69: 19-26.
13. Kanayama G, Pope HG, Cohane G, et al,. Risk factors for anabolic-androgenic steroid use among weightlifters: A case-control study. Drug Alcohol Depend. 2003; 71: 77-86.
14. Skarberg K, Nyberg F, Engstrom I,. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Euro Addict Res. 2009; 15: 99-106.
15. Ayuk J, Sheppard MC,. Does acromegaly enhance mortality? Rev Endocr Metab Disord. 2008; 9: 33-39.
16. Melmed S,. Medical progress: Acromegaly. N Engl J Med. 2006; 355: 2558-2573.
17. Orme SM, McNally RJ, Cartwright RA, et al,. United Kingdom Acromegaly Study Group. Mortality and cancer incidence in acromegaly: A retrospective cohort study. J Clin Endocrinol Metab. 1998; 83: 2730-2734.
18. Colao A,. The GH-IGF-I axis and the cardiovascular system: Clinical implications. Clin Endocrinol. 2008; 69: 347-358.
19. Colao A, Vitale G, Pivonello R, et al,. The heart: An end-organ of GH action. Eur J Endocrinol. 2004; 151 (Suppl 1): S93-101.
20. Lombardi G, Galdiero M, Auriemma RS, et al,. Acromegaly and the cardiovascular system. Neuroendocrinology. 2006; 83: 211-217.
21. Jorgensen JO, Moller L, Krag M, et al,. Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North Am. 2007; 36: 75-87.
22. Luboshitzky R, Barzilai D,. Hypoxemia and pulmonary function in acromegaly. Am Rev Respir Dis. 1980; 121: 471-475.
23. Matano Y, Okada T, Suzuki A, et al,. Risk of colorectal neoplasm in patients with acromegaly and its relationship with serum growth hormone levels. Am J Gastroenterol. 2005; 100: 1154-1160.
24. Jenkins PJ,. Cancers associated with acromegaly. Neuroendocrinology. 2006; 83: 218-223.
25. Kanayama G, Hudson JI, Pope HG,. Demographic and psychiatric features of men with anabolic-androgenic steroid dependence: A comparative study. Drug Alcohol Depend. 2009; 102: 130-137. NIHMS 116485.
26. First M, Spitzer R, Gibbon M, et al,. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York: Biometrics Research Department, New York State Psychiatric Institute; 2001.
27. Kouri EM, Pope HG, Jr, Katz DL, et al,. Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clin J Sport Med. 1995; 5: 223-228.
28. Kanayama G, Brower KJ, Wood RI, et al,. Issues for DSM-V: Clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009; 166: 642-644. NIHMSID 109288.
29. Olshansky SJ, Perls TT,. New developments in the illegal provision of growth hormone for "anti-aging" and bodybuilding. JAMA. 2008; 299: 2792-2794.
30. Ehrnborg C, Rosen T,. Physiological and pharmacological basis for the ergogenic effects of growth hormone in elite sports. Asian J Androl. 2008; 10: 373-383.
31. Gibney J, Healy ML, Sonksen PH,. The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr Rev. 2007; 28: 603-624.
32. Graham MR, Baker JS, Evans P, et al,. Potential benefits of recombinant human growth hormone (rhGH) to athletes. Growth Horm IGF Res. 2009; 19: 300-307.
33. Graham MR, Davies B, Grace FM, et al,. Anabolic steroid use: Patterns of use and detection of doping. Sports Med. 2008; 38: 505-525.
34. Graham MR, Baker JS, Evans P, et al,. Physical effects of short-term recombinant human growth hormone administration in abstinent steroid dependency. Horm Res. 2008; 69: 343-354.
35. Graham MR, Baker JS, Evans P, et al,. Short-term recombinant human growth hormone administration improves respiratory function in abstinent anabolic-androgenic steroid users. Growth Horm IGF Res. 2007; 17: 328-335. (Pubitemid 47109216)
36. Baggish A, Weiner RB, Kanayama G, et al,. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation: Heart Failure. 2010; 3: 472-476.
37. Kanayama G, Hudson JI, Pope HG, Jr,. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: A looming public health concern? Drug Alcohol Depend. 2008; 98: 1-12.
38. Cittadini A, Berggren A, Longobardi S, et al,. Supraphysiological doses of GH induce rapid changes in cardiac morphology and function. J Clin Endocrinol Metab. 2002; 87: 1654-1659.
39. Feise RJ,. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol. 2002; 2: 8.
40. Savitz DA, Olshan AF,. Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol. 1995; 142: 904-908.